Neurocognitive Effects of Zidovudine and 2′,3′-Dideoxyinosine During the Treatment of Asymptomatic and Symptomatic HIV-1 Seropositive Patients. Comparison with Non-Treated Patients
✍ Scribed by D. DE RONCHI; C. LAZZARI; P. RUCCI; A. CANGIALOSI; V. VOLTERRA
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 606 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0885-6222
No coin nor oath required. For personal study only.
✦ Synopsis
This paper reports the results of the cross-sectional phase of a long-term follow-up investigation, carried out on a sample representative of the broad population of HIV-1 infected patients, with the objective of evaluating the possible neurocognitive effects of zidovudine and 2', 3'-dideoxyinosine, compared to a group of people who refused antiretroviral therapy. The sample was composed of 88 people, 42 of whom were treated with ZDV at a daily dose of 500-600 mg, 19 with ddI at a daily dose of 400 mg, and 27 with no therapy. To assess the relevance of different antiretroviral therapies on cognitive performance adjusting for demographic and clinical characteristics, a stepwise logistic regression analysis was performed with neuropsychological performance as the dependent variable and age, educatian, sex, at-risk behaviour, C'D4 count, presence of prominent depressive and anxious symptoms, HIV-1 serostatus and type of antiretroviral treatment as independent variables. The results confirm that people with AIDS and AIDS-related complex treated with ZDV and ddI show a better neuropsychological performance when compared to non-treated patients. By examining the mean performance on each of the previous neuropsychological tests, we found that the most impaired functions in untreated patients were related to short-term memory, long-term memory, vocational competence, and ultimate adjustment.